Dimethyl sulfoxide (DMSO) has previously been reported to protect against hepatotoxicity resulting from chloroform (CHCl 3 ) or bromobenzene (BB) when given 10 hr after the toxicant. The object of these studies was to further demonstrate the latent protective ability of DMSO by administering it at a much later time (24 hr) following toxicant exposure. In addition, a more detailed evaluation of the lesions was performed to better characterize the lesion progression and resolution. Male Sprague-Dawley rats received a hepatotoxic oral dose of either CHCl 3 (1.0 ml/kg) or BB (0.5 ml/kg) and then received 2 ml/kg DMSO intraperitoneally 24 hr later. With both toxicants, limited centrilobular lesions were already present by the time DMSO was administered. Without treatment, liver injury rapidly progressed so that by 48 hr it occupied 40-50% of the liver, with accompanying large increases in plasma alanine aminotransferase (ALT) activity. Administration of DMSO greatly attenuated lesion development for both toxicants; the area injured was reduced by more than 4-fold, accompanied by a decrease in 48 hr ALT activity of 8-16-fold. The ability of DMSO to intervene in the development of liver injury at such a late time appears to be unique and may provide insight into therapies for acute xenobioticinduced hepatitis.
Hepatoprotection by Dimethyl Sulfoxide. I. Protection When Given
Twenty-Four Hours After Chloroform or Bromobenzene* INTRODUCTION Dimethyl sulfoxide (DMSO) has been long recognized for its beneficial properties as an anti-inflammatory agent and as an effective treatment for ischemia in a variety of tissues (2-4, 20, 24, 28) . In addition, DMSO has the ability to protect against xenobiotic-induced liver injury if administered prior to or within a few hours of the toxicant (1, 21, 26) . Even late administration of DMSO has exceptional protective actions in several animal models of hepatic injury (18) . When given 10 hr after the toxicant, DMSO protected against the hepatotoxicity resulting from inhalation exposure to halothane in the guinea pig. It also protected the livers of rats from oral doses of either chloroform (CHCI3) or bromobenzene (BB). To better demonstrate the latent ability of DMSO to inhibit the progression of injury, studies were undertaken in which the time of DMSO administration was extended to 24 hr after toxicant dosing. In addition, the protection was characterized to a greater extent through more detailed observations of lesion pathology. By waiting until 24 hr after CHCl3 or BB exposure to administer DMSO, it would be expected that the events responsible for initiation of liver injury would have occurred and that the development of necrosis would be underway (23, 27, 29) , providing further insight into the potential for DMSO as a treatment for acute progressing hepatitis.
MATERIALS AND METHODS

'
Animal Treatments. All animal treatments were made in accordance with a protocol approved by the University of Arizona Animal Care Committee. All animals received food and water ad libitum.
Groups of male Sprague-Dawley rats (300-325 g; Harlan Sprague Dawley, Indianapolis, IN) were administered either 1.0 ml/kg CHCI, or 0.5 ml/kg BB (Sigma Chemical Co., St. Louis, MO), 20% in corn oil, by oral gavage. A subset of the animals from each of these groups (n = 4) were euthanatized at 18 hr and 24 hr after toxicant dosing. The remainder of the CHC'3-and BB-treated animals received intraperitoneal (ip) injections of either 4 ml/kg saline or 2 ml/kg DMSO (Sigma Chemical Co.), 50% in saline, at 24 hr after administration of the toxicants.
Groups of animals thus treated (n = 4-7) were then euthanatized at 48 and 72 hr after toxicant dosing. Control animals (n = 6) were given corn oil by oral gavage and then either saline or DMSO ip 24 hr later. The control animals were then euthanatized 48 hr after corn oil administration.
Sample Collection and Analysis. After administration of a lethal ip dose of pentobarbital, cardiac blood was collected while the animals were under deep anesthesia.
Livers were then removed after cardiac arrest. Transverse slices of liver tissue, one each from the three largest lobes, were placed in neutral buffered formalin for several days prior to processing. Plasma samples were analyzed for alanine aminotransferase (ALT) activity (procedure 59-UV, Sigma Chemical Co.).
One randomly selected slice of formalin-fixed liver tissue from each animal was dehydrated in alcohol, cleared in xylene, and infiltrated with paraffin. Five-micrometerthick sections were then stained with Gills II hematoxylin and eosin Y. Liver sections were then evaluated by light microscopy. Because liver injury was maximal at 48 hr after toxicant dosing, tissue sections taken at this time were then quantitated for the extent of injury to allow for FIG. 1.-Effect of DMSO administration on plasma ALT activity in rats following an oral dose of CHCh or BB. CHCI 3 + saline = 1.0 ml/kg CHC'3, 20% in corn oil po, followed by 4 ml/kg saline ip 24 hr later. BB + saline = 0.5 ml/kg BB, 20% in corn oil po, followed by saline 24 hr later. CHC'3 + DMSO =-CHC13 followed by 2 ml/kg DMSO, 50% in saline ip 24 hr later. BB + DMSO = BB followed by DMSO 24 hr later. Some symbols are offset slightly for clarity * p < 0.05 vs control (0 hr) value (35 ± 2 U/L, n = 6). ** p < 0.001 vs CHC'3 + saline or BB + saline value at the same time point. Values are x -~-SE, n = 4-7.
comparisons between treatment groups. Quantitation was accomplished utilizing Bioquant BQ-05/2, version 2.60 (R&M Biometrics, Nashville, TN). Light microscopic video images of 0.5-mm2 liver tissue sections that contained 2-4 centrilobular and periportal regions each were displayed at X270 magnification and frame captured. Injured areas, which included hepatocytes necrosis and hepatocytes that had undergone ballooning degeneration, were then outlined, excluding the area inside the central veins. If a major blood vessel occupied more than 25% of the image, another area was selected. Eight randomly selected images from 1 tissue section per animal were measured. The areas of injury were divided by the area viewed to provide a percentage area of injury for each liver.
Statistical Analysis. All values are expressed as mean sue of the mean. Time course values for ALT activity were compared by analysis of variance with a Newman-Keuls multiple comparison test that included values from the control animals. Comparisons of the extent of liver injury were made with a 2-tailed Student's t-test. A log transformation of ALT activity values was made prior to analysis. A p value of <0.05 was considered significant.
RESULTS
Development of CHCl3-Induced Liver Injury
By 18 hr after CHCl3 dosing, a centrilobular lesion was already present. Numerous foci of hepatocyte necrosis, often with an associated infiltrate of mononuclear inflammatory cells, were visible in the centrilobular regions. Hepatocytes 1-4 cells deep surrounding the central veins showed the onset of ballooning degeneration. Plasma ALT activity was already significantly increased above control values at this time ( Fig. 1 ). At 24 hr after CHCI, dosing, the centrilobular injury had increased in its extent from that present at 18 hr ( Fig. 2a ). Areas of confluent hepatocyte necrosis and greater numbers of hepatocytes showing ballooning degeneration were evident. Plasma ALT activity demonstrated a concomitant 20-fold increase above control values at this time (Fig. 1 ). In the animals that received only saline at 24 hr after CHCl3 dosing, liver injury continued to progress, so that by 48 hr after dosing, injury bridged many centrilobular areas (Fig. 2b, c) . The injury, with its areas of hepatocyte necrosis, infiltrating mononuclear inflammatory cells, and ballooning degeneration of hepatocytes, now occupied 40% of the liver on average (Fig. 3 ). This extension of the liver injury was accompanied by a large increase in ALT activity (Fig. 1 ). By 72 hr after CHCl3 dosing, plasma ALT had decreased, but the liver injury was similar in extent to that seen at 48 hr.
Effect of DMSO on CHCI, Hepatotoxicity
Treatment with DMSO 24 hr after CHCl3 dosing attenuated further development of the injury. By 48 hr after CHC13 dosing, there were decreases of 90% in plasma ALT activity and 75% in the extent of resultant injury in the animals that received DMSO as compared with the animals that received saline (Figs. 1, 2d, e, 3 ). The appearance of the liver injury differed between the treatment groups only in the extent of injury and not in its histologic pattern (Fig. 2c, e ). There was no change in plasma ALT activity from 48 hr to 72 hr (Fig. 1 ). Again, the liver injury appeared no greater in extent at 72 hr than at 48 hr.
Development of BB-Induced Liver Injury
At 18 hr after an oral dose of BB, the centrilobular regions displayed multiple, scattered, single-celled to confluent foci of hepatocyte necrosis with associated mononuclear inflammatory cell infiltrates. However, plasma ALT activity was not increased above control values at this time (Fig. 1 ). By 24 hr, the centrilobular foci of confluent hepatocyte necrosis were more evident (Fig.  4a ). Plasma ALT activity at 24 hr had yet to significantly increase above control values (Fig. 1 ). Over the next 24 hr, a lesion characterized by coagulative necrosis developed very rapidly, so that by 48 hr, it occupied over 50% of the liver (Figs. 3, 4b, c ). There were numerous dead and dying hepatocytes in the centrilobular regions at this time, with disruption of acinus architecture and associated congestion. Mononuclear cells were infiltrating the necrotic regions. Development of this extensive necrosis was accompanied by large increases in ALT activity at 48 hr (Fig. 1) . By 72 hr after BB, plasma ALT activity had decreased by 90% as compared with 48-hr values (Fig. 1) . Along with the resolution of increased ALT activity, the liver injury at 72 hr was similar in extent to that observed at 48 hr.
Effect of DMSO on BB Hepatotoxicity
By giving DMSO 24 hr after BB dosing, most of the progression of injury was prevented. At 48 hr after dosing, ALT activity and the extent of necrosis were decreased by 95% and 75%, respectively, compared with that of the animals that received BB followed by saline ( Figs. 1, 3, 4d, e ). Although DMSO treatment greatly altered the extent of BB-induced injury, it did not affect its histologic pattern of injury (Fig. 4c, e ). At 72 hr, ALT activity in the BB + DMSO-treated animals was not different from control values (Fig. 1) , and the centrilobular injury in these animals appeared similar to that seen at 48 hr.
DISCUSSION
More than 30 yr ago, DMSO was being used in extensive clinical trials in the United States. Just short of being approved by the Food and Drug Administration for a number of conditions, a change in the refractive index of the lens of experimental animals receiving very high chronic doses of DMSO caused a halt in the clinical studies (5) . Even though thousands of human case reports were collected with no signs of overt toxicity and a subsequent human toxicology study found chronic use to be safe, DMSO maintains an Investigative New Drug status to this day, with the only approved use in humans in this country being for interstitial cystitis (4, 5) . Approved veterinary uses are topical application to horses for acute swelling due to trauma and otic application to dogs for inflammation in a solution that also contains a steroid. In addition to its reputation as an anti-inflammatory agent and as a treatment for ischemic injury, DMSO is well known as a transporter of substances through the skin, a cryopreservative, a radioprotectant, a diuretic, an analgesic, and an essential ingredient in media for long-term culture of hepatocytes (4, 13) .
In the present studies, we have demonstrated that DMSO also has the ability to interrupt the acute, progressing liver toxicity caused by either CHCl3 or BB when administered at a time when the injury had developed to a point where centrilobular lesions were already present. Although injury continued to rapidly worsen in the rats that did not receive DMSO therapy, treatment with DMSO produced an attenuation in development of both the ballooning vacuolization and necrosis of hepatocytes caused by CHCI, and the frank coagulative necrosis produced by BB. This protective action was not simply due to a delay in the progression of lesion development because plasma ALT activity remained low even at 48 hr after DMSO administration, i.e., 72 hr after the toxicant was given, and the extent of injury was not visibly worsening at this time.
The naive rats used in this study did not develop maximal injury until 48 hr after toxicant administration. This is a much later time than that observed for rats that have been fasted or pretreated with biotransformation-enhancing agents (12, 22, 27, 29) . These findings underscore the need to investigate the time course of lesion development when performing hepatotoxicity studies to avoid misleading results by using only a single time for comparison (6) .
Except for a recent study in which DMSO was given 10 hr after toxicant exposure (18) , other studies utilizing DMSO as a protectant have called for its administration prior to, concomitant with, or, at best, no longer than a few hours after a toxicant (1, 21, 26) . Other antidotes for either CHCI3or BB-induced hepatic injury have also had to be administered at much earlier times to be effective (10, 11, 16) . Thus, the results of this study on the ability of DMSO to intervene in the progression of hepatic necrosis when given at such a late time after CHCI, or BB appear to be unique.
The mechanism(s) of the protection produced by late administration of DMSO is unclear. There are a number of physiologic effects of DMSO that could contribute to protection, including its ability to inhibit biotransformation, enhance tissue blood flow after injury, reduce an inflammatory response, and scavenge free radicals (7, 19, 20, 25, 28) .
DMSO is well known as an inhibitor of cytochrome P-450 enzymes that are responsible for the bioactivation of CHCl3 and BB to their toxic reactive intermediates (7, 19) . This inhibition could help prevent the development of necrosis if the quantities of CHCl3 and BB remaining at 24 hr after their administration were still contributing to the progressing hepatic injury (8, 23) . DMSO also has the ability to prevent platelet aggregation and adhesion and to affect prostaglandin synthesis (14, 24, 28) . These effects could benefit liver homeostasis by helping to maintain sinusoidal perfusion, the loss of which has been implicated in the development of xenobiotic-induced liver injury (17) .
Other effects of DMSO, such as reducing inflammatory cell recruitment, chemotaxis, and release of oxidizing species (2, 3, 20) , may decrease the role that the inflammatory response plays in the liver injury after an initial insult (15, 30) . Some of the anti-inflammatory effects of DMSO may be due to its capacity to inhibit activation of the transcription factor NF-KB and the subsequent production of chemokines (9, 20) , which has been attributed to the ability of DMSO to scavenge reactive oxygen species, interrupting modulation of signal transduction pathways (9) . The many potentially beneficial effects of DMSO in- dicate that the hepatoprotective actions observed in this study may be multifactorial in nature. Future studies will explore these possible mechanisms of protection by late administration of DMSO and may provide insight into therapeutics for individuals suffering from acute, progressing xenobiotic-induced hepatitis.
